Surgalign Holdings Inc

Surgalign — Investor Day (November 2020)

58 slides from Surgalign's investor day presentation, Nov 12, 2020

  1. Slide 1: Virtual Investors' Day November 12, 2020

    Slide 1: Virtual Investors' Day November 12, 2020

    Exhibit 99.1 Virtual Investors’ Day November 12, 2020Exhibit 99.1 Virtual Investors’ Day November 12, 2020

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s

  3. Slide 3: Terry Rich, President & Chief Executive Officer

    Slide 3: Terry Rich, President & Chief Executive Officer

    Terry Rich President & Chief Executive Officer 3Terry Rich President & Chief Executive Officer 3

  4. Slide 4: Today's Agenda

    Slide 4: Today's Agenda

    Today’s Agenda Vision and Strategy — Terry Rich, CEO Functional Overviews - Products and Innovation — Doug Bireley, EVP, Marketing and R&D - Research, Clinical Affairs, Surgeon Education: G. Bryan Cornwall PhD, EVP, Research & Clinical Affairs - Commercial Strategy — Scott Durall, CCO & Enrico Sangi

  5. Slide 5: CEO's View of Surgalign

    Slide 5: CEO's View of Surgalign

    CEO’s View of Surgalign Attracted by several things: - $125M revenue (2019) with broad portfolio to build on - Clean balance sheet to fuel strategic initiatives - Established International platform - Demonstrated ability to drive growth - Ingrained commitment to clinical data - Large, diverse distri

  6. Slide 6: The Launch of Surgalign

    Slide 6: The Launch of Surgalign

    The Launch of Surgalign We stood Surgalign up on July 20, 2020, with a mission to align with surgeons to improve patient lives by developing and delivering intelligent solutions for spine disorders. ​ Nine weeks later, announced deal to acquire Holosurgical and its industry-redefining ARAI™ digital

  7. Slide 7: CEO's Perspective on Progress – First 90 days

    Slide 7: CEO's Perspective on Progress – First 90 days

    st CEO’s Perspective on Progress – 1 90 days Key accomplishments since becoming chief executive in July: Completed separation from OEM and established SRGA as a global pure-play spine company Navigated global COVID-19 business impact Built a world class leadership team Designed New Product Road Map

  8. Slide 8: Surgalign Strategic Pillars

    Slide 8: Surgalign Strategic Pillars

    Surgalign Strategic Pillars Organically develop Acquire to drive Build and optimize new high-value clinically differentiation and scale, a global spine validated solutions that and add enabling infrastructure and will enhance standard technologies organization of careSurgalign Strategic Pillars Orga

  9. Slide 9: Strategic Drivers: Win by Improving Patient Outcomes

    Slide 9: Strategic Drivers: Win by Improving Patient Outcomes

    STRATEGIC DRIVERS: WIN BY IMPROVING PATIENT OUTCOMES Embrace and partner with surgeon thought leaders Harness transformative, clinically-validated innovation Differentiate core and biomaterials products Lead the way in digital surgerySTRATEGIC DRIVERS: WIN BY IMPROVING PATIENT OUTCOMES Embrace and p

  10. Slide 10: Proven Executive Leadership Team

    Slide 10: Proven Executive Leadership Team

    Proven Executive Leadership Team Jon Singer Scott Durall Kris Siemionow Robert Watkins Chief Financial & Operating Chief Medical Officer Chief Commercial Officer Chief Technology Officer Officer 1998 Terry Rich President & CEO Josh DeRienzis G. Bryan Cornwall Doug Bireley Enrico Sangiorgio Renu Mene

  11. Slide 11: Doug Bireley, EVP, Marketing and R&D

    Slide 11: Doug Bireley, EVP, Marketing and R&D

    Doug Bireley, EVP, Marketing and R&D Portfolio overview Innovation road map 11Doug Bireley, EVP, Marketing and R&D Portfolio overview Innovation road map 11

  12. Slide 12: Portfolio Assessment – Procedural Coverage

    Slide 12: Portfolio Assessment – Procedural Coverage

    Portfolio Assessment – Procedural Coverage Strong product coverage by procedure type Balanced performance between U.S. / Intl. markets - Products cover 87% of core spine surgeries - Biomaterial offering covers 70% of spine-related uses GLOBAL SPINE HARDWARE MARKET, $12B SURGALIGN REVENUE 2020 YTD (D

  13. Slide 13: Portfolio Assessment – Short Term Opportunities

    Slide 13: Portfolio Assessment – Short Term Opportunities

    Portfolio Assessment – Short Term Opportunities +14.5% +5.2% +20.0% 3D printed Ti Cage Market Biomaterials Market International Market 13Portfolio Assessment – Short Term Opportunities +14.5% +5.2% +20.0% 3D printed Ti Cage Market Biomaterials Market International Market 13

  14. Slide 14: Pipeline Strategy

    Slide 14: Pipeline Strategy

    Pipeline Strategy Develop best-in-class posterior screw system Compete in traditional Lateral & ATP space Build upon our #2 position in SI Joint Expand differentiated BioMaterials portfolio Create seamless integration with Holosurgical Digital Platform Source: 2020 Orthostreams.com 14Pipeline Strate

  15. Slide 15: Organizational Capabilities

    Slide 15: Organizational Capabilities

    Organizational Capabilities R&D Centers of Excellence in San Diego, CA & Wurmlingen, Germany Digital Surgery Innovation Center in Warsaw, Poland Harness new capabilities in artificial intelligence and predictive analytics via Holosurgical Digital Platform Align our efforts with the best surgeon KOLs

  16. Slide 16: G. Bryan Cornwall, EVP, Research & Clinical Affairs

    Slide 16: G. Bryan Cornwall, EVP, Research & Clinical Affairs

    G. Bryan Cornwall, PhD, MBA, PEng EVP, Research & Clinical Affairs Research Strategy Surgeon Education 16G. Bryan Cornwall, PhD, MBA, PEng EVP, Research & Clinical Affairs Research Strategy Surgeon Education 16

  17. Slide 17: Research Strategy

    Slide 17: Research Strategy

    Research Strategy Positive MDR audit & certificate Focus on clinical outcomes: >100 coflex, HPS, Holo, etc. Leverage previous research experience for future Holosurgical Digital Platform publication strategy 17Research Strategy Positive MDR audit & certificate Focus on clinical outcomes: >100 coflex

  18. Slide 18: Surgeon Education

    Slide 18: Surgeon Education

    Surgeon Education Design Center of Excellence in San Diego, CA Digital platform intuitive design Holosurgical Digital Platform driver for procedural solutions = very important for Surgeon Education & Clinical Research 18Surgeon Education Design Center of Excellence in San Diego, CA Digital platform

  19. Slide 19: Commercial – Scott Durall, Chief Commercial Officer

    Slide 19: Commercial – Scott Durall, Chief Commercial Officer

    Commercial Scott Durall, Chief Commercial Officer 19Commercial Scott Durall, Chief Commercial Officer 19

  20. Slide 20: Commercial Strategy – Current

    Slide 20: Commercial Strategy – Current

    Commercial Strategy CURRE NT Top-10 market share Pure-play, standalone spine company Broad hospital/IDN/GPO contractual access Multiple specialized sales teams Separate/conflicting distribution channels Product portfolio gaps 20Commercial Strategy CURRE NT Top-10 market share Pure-play, standalone s

  21. Slide 21: Commercial Strategy – Future

    Slide 21: Commercial Strategy – Future

    Commercial Strategy F UT URE Salesforce expansion, integration & alignment Surgeon & distributor penetration New product launches Biomaterials Ti Plus Interbodies ASC/outpatient procedural shift 21Commercial Strategy F UT URE Salesforce expansion, integration & alignment Surgeon & distributor penetr

  22. Slide 22: Commercial Strategy

    Slide 22: Commercial Strategy

    Commercial Strategy Direct-to-Surgeon engagement - Digital Surgery Education & Training program o Comprehensive procedural solutions Full-line Distributors partners Expanded Hospital Access & Committed Purchasing Agreements 22Commercial Strategy Direct-to-Surgeon engagement - Digital Surgery Educati

  23. Slide 23: Commercial – Enrico Sangiorgio, EVP International

    Slide 23: Commercial – Enrico Sangiorgio, EVP International

    Commercial Enrico Sangiorgio, EVP International 23Commercial Enrico Sangiorgio, EVP International 23

  24. Slide 24: International Business Outlook

    Slide 24: International Business Outlook

    International Business Outlook PRIORITY MARKETS CAN DELIVER: EUROPEAN OPERATIONS Warsaw • Poland o Double-digit growth Holosurgical Augmented Reality & Artificial Intelligence Healthy contribution margins Key Target Markets - Germany, UK, Italy, Spain, Australia, - Poland, Belgium, Taiwan, China, Vi

  25. Slide 25: Optimized Sales Channel with Unique Product Offering

    Slide 25: Optimized Sales Channel with Unique Product Offering

    Optimized Sales Channel with unique product offering Fully direct: Germany, Poland and Belgium Semi-direct: UK, Spain, Italy and Australia Stocking distributors for rest of OUS 25 HPS 2.0 STREAMLINE F FORTILINK INTERBODY WITH TiPLUSOptimized Sales Channel with unique product offering Fully direct: G

  26. Slide 26: Near Term Opportunities

    Slide 26: Near Term Opportunities

    Near term opportunities 11 Key product launches between Q4 2020 and Q2 2021 - HPS 2.0 dynamic hybrid system - Streamline F both MIS and Open - TiPlus range - Tetrafuse (CE pending) - Streamline OCT (CE pending) Operational growth enablers - Complete unified Sales Force in Germany, Poland, Belgium an

  27. Slide 27: Dr. Kris Siemionow – HOLO Overview

    Slide 27: Dr. Kris Siemionow – HOLO Overview

    Dr. Kris Siemionow, MD, PhD Holosurgical Co-Founder HOLO Overview 27Dr. Kris Siemionow, MD, PhD Holosurgical Co-Founder HOLO Overview 27

  28. Slide 28: HoloSurgical – A Digital Surgery Company Focused on Spine

    Slide 28: HoloSurgical – A Digital Surgery Company Focused on Spine

    HoloSurgical - A Digital Surgery Company Focused on Spine We have developed an AI-based platform technology applicable across ALL of orthopedics, soft tissue, and general surgery *Holosurgical Digital Platform and ARAI Technology have not been evaluated by the FDA 28HoloSurgical - A Digital Surgery

  29. Slide 29: HoloSurgical – A Quick History

    Slide 29: HoloSurgical – A Quick History

    HoloSurgical – A Quick History In 2013 we started looking for better ways of doing CAS A quote from a surgeon in the audience really stuck with me: “Robots are blind and dumb so why would I want to use one” -Anonymous Spine Surgeon *Holosurgical Digital Platform and ARAI Technology have not been eva

  30. Slide 30: Evolution of Surgery

    Slide 30: Evolution of Surgery

    Evolution of Surgery The main barriers to the development of next generation MIS systems are limited visualization and a lack of intelligence, restricting functionality SURGERY 4.0 and prolonging surgery time. (Intelligent Surgery) Smart Augmented Instruments / OPEN SURGERY MIS & Navigation ROBOTS R

  31. Slide 31: Holosurgical: Free Standing Surgical Guidance Platform

    Slide 31: Holosurgical: Free Standing Surgical Guidance Platform

    Holosurgical: Free Standing Surgical Guidance Platform The Holosurgical System is an advanced surgical guidance platform that combines: o 3D visualization o data analytics o artificial intelligence in order to: o improve outcomes o reduce surgical time o decrease complications *Holosurgical Digital

  32. Slide 32: HoloSurgical = we taught the computer anatomy

    Slide 32: HoloSurgical = we taught the computer anatomy

    HoloSurgical = we taught the computer anatomyHoloSurgical = we taught the computer anatomy

  33. Slide 33: Once you teach the computer anatomy

    Slide 33: Once you teach the computer anatomy

    Once you teach the computer anatomyOnce you teach the computer anatomy

  34. Slide 34: Everything is possible.

    Slide 34: Everything is possible.

    Everything is possible.Everything is possible.

  35. Slide 35: Augmented Reality, Predictive Analytics, Smart Instruments

    Slide 35: Augmented Reality, Predictive Analytics, Smart Instruments

    AUGMENTED REALITY PREDICTIVE ANALYTICS AUTONOMOUS PLANNING C SMART INSTRUMENTS AUTONOMOUS GUIDANCE PERSONALIZED 3D PRINTING D IAG N O STI C S SMART ROBOTSAUGMENTED REALITY PREDICTIVE ANALYTICS AUTONOMOUS PLANNING C SMART INSTRUMENTS AUTONOMOUS GUIDANCE PERSONALIZED 3D PRINTING D IAG N O STI C S SMAR

  36. Slide 36: Holosurgical Solutions: Complete Continuum of Care

    Slide 36: Holosurgical Solutions: Complete Continuum of Care

    Holosurgical Solutions: Complete Continuum of Care P REOP E R AT I V E I N T RAO PE RAT I V E P OSTOP E RAT I V E OUTPATIENT SOLUTIONS OUTPATIENT SOLUTIONS SOLU T ION S Diagnostics and Analytics Diagnostics and Analytics MRI/CT/Xray MRI/CT/Xray *Holosurgical Digital Platform and ARAI Technology have

  37. Slide 37: HOLO Provides Keys to Digital Surgery Capability

    Slide 37: HOLO Provides Keys to Digital Surgery Capability

    HOLO PROVIDES KEYS TO DIGITAL SURGERY 5 CAPABILITY 1. Automatic Image Processing/Segmentation 2. Smart Instruments 3. Augmented Reality + Advanced Visualization 4. Patient Specific Procedures 5. Artificial Intelligence + Predictive Analytics *Holosurgical Digital Platform and ARAI Technology have no

  38. Slide 38: Automatic Image Processing/Segmentation

    Slide 38: Automatic Image Processing/Segmentation

    Automatic Image Processing/Segmentation 1 Autonomous Spine Level Identification and Separation - Driven by Machine Learning Algorithms* Advantages of AI algorithms at work - Algorithm learned how to identify spinal levels o Automatically recognizes cervical, thoracic, lumbar segments o Automatically

  39. Slide 39: Smart Instruments

    Slide 39: Smart Instruments

    Smart Instruments 2 Laminectomy + Smart Burr Pre Resection Post Resection Stop Stop Computer simulated resection planes *Holosurgical Digital Platform and ARAI Technology have not been evaluated by the FDA 40Smart Instruments 2 Laminectomy + Smart Burr Pre Resection Post Resection Stop Stop Computer

  40. Slide 40: Augmented Reality + Advanced Visualization

    Slide 40: Augmented Reality + Advanced Visualization

    Augmented Reality + Advanced Visualization 3 TM TM ARAI System Summary: “Smart X-Ray Vision ” Smart Guidance X-Ray Vision (Artificial (Augmented Intelligence Reality Software) Software) *Holosurgical Digital Platform and ARAI Technology have not been evaluated by the FDA 41Augmented Reality + Advanc

  41. Slide 41: Patient Specific Procedures via Robust Software Application

    Slide 41: Patient Specific Procedures via Robust Software Application

    Patient Specific Procedures via Robust Software Application 4 Scoliosis Segmentation Revolutionize Personalized 3D Printing Bone Density Disc Segmentation Congenital Scoliosis Idiopathic Scoliosis Extra bone! 42Patient Specific Procedures via Robust Software Application 4 Scoliosis Segmentation Revo

  42. Slide 42: Artificial Intelligence + Predictive Analytics

    Slide 42: Artificial Intelligence + Predictive Analytics

    Artificial Intelligence + Predictive Analytics 5 AI has potential for a wide range of applications: Case specific implant delivery Auto identifies implant size, bone density, volume, parameters Reduces wrong level surgery Guides smart instrument on where to perform procedure Essential for personaliz

  43. Slide 43: Surgical Workflow

    Slide 43: Surgical Workflow

    Surgical Workflow There are multiple options for seamless integration into the surgeon’s existing workflow AR-Based 3D Autonomous Autonomous Pre-op Intra-op Surgery with OPTION 1 Software Registration and Scan Scan Autonomous Planning Anatomy I.D. Guidance AR-Based 3D Autonomous Autonomous Surgery w

  44. Slide 44: HoloSurgical = we taught the computer anatomy

    Slide 44: HoloSurgical = we taught the computer anatomy

    HoloSurgical = we taught the computer anatomyHoloSurgical = we taught the computer anatomy

  45. Slide 45: Once you teach the computer anatomy

    Slide 45: Once you teach the computer anatomy

    Once you teach the computer anatomyOnce you teach the computer anatomy

  46. Slide 46: Everything is possible

    Slide 46: Everything is possible

    Everything is possibleEverything is possible

  47. Slide 47: Everything is possible

    Slide 47: Everything is possible

    Everything is possibleEverything is possible

  48. Slide 48: Everything is possible

    Slide 48: Everything is possible

    Everything is possibleEverything is possible

  49. Slide 49: Everything is possible

    Slide 49: Everything is possible

    Everything is possibleEverything is possible

  50. Slide 50: Everything is possible

    Slide 50: Everything is possible

    Everything is possibleEverything is possible

  51. Slide 51: Jon Singer – Financial Overview

    Slide 51: Jon Singer – Financial Overview

    Jon Singer Chief Financial & Operating Officer Financial Overview 52Jon Singer Chief Financial & Operating Officer Financial Overview 52

  52. Slide 52: Key Accomplishments for 2020

    Slide 52: Key Accomplishments for 2020

    Key Accomplishments for 2020 Completed separation from OEM and established SRGA as a global pure-play spine company Navigated global COVID-19 business impact Built a world class leadership team Designed New Product Road Map Initiated Salesforce integration Acquired a leading position in the future o

  53. Slide 53: Milestones for 2021

    Slide 53: Milestones for 2021

    Milestones for 2021 Complete Salesforce integration and continue optimization Accelerate our innovation agenda FDA Clearance of Holo technology Launch multiple IRB sites to build clinical evidence and to continue development of intelligent surgery Return to growth – position us for attractive double

  54. Slide 54: Multiple Drivers of Growth

    Slide 54: Multiple Drivers of Growth

    Multiple Drivers of Growth Portfolio refresh and new product introductions Reinforce commitment to clinical evidence Strengthen distributor integration and leverage superior contractual access Leverage international platform Holo launch, placements and product pull-through Opportunistic distribution

  55. Slide 55: Key Financial Metrics

    Slide 55: Key Financial Metrics

    Key Financial Metrics REVENUE BY PRODUCT CATEGORY SURGALIGN REVENUE 2020 YTD (HARDWARE VS. BIOLOGICS, MRQ) (DOMESTIC VS INTERNATIONAL, MRQ) Domestic Hardware 83% 77% Biologics International 23% 17% 56Key Financial Metrics REVENUE BY PRODUCT CATEGORY SURGALIGN REVENUE 2020 YTD (HARDWARE VS. BIOLOGICS

  56. Slide 56: 2023 Targeted Metrics

    Slide 56: 2023 Targeted Metrics

    2023 Targeted Metrics DOUBLE 10-13% 75% >50% ~ DIGIT R&D as a Revenue Growth Gross Margin Vitality Index % of Revenue 572023 Targeted Metrics DOUBLE 10-13% 75% >50% ~ DIGIT R&D as a Revenue Growth Gross Margin Vitality Index % of Revenue 57

  57. Slide 57: Q & A

    Slide 57: Q & A

    Q & A 58Q & A 58

  58. Slide 58: Surgalign Spine Technologies

    Slide 58: Surgalign Spine Technologies

Source: SEC EDGAR · 8-K filed Nov 12, 2020

More decks from Surgalign Holdings Inc